171 related articles for article (PubMed ID: 35293685)
1. Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia.
McClane J; Chawla A; Welch JJG
Pediatr Blood Cancer; 2022 Jun; 69(6):e29664. PubMed ID: 35293685
[TBL] [Abstract][Full Text] [Related]
2. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.
Raetz EA; Cairo MS; Borowitz MJ; Lu X; Devidas M; Reid JM; Goldenberg DM; Wegener WA; Zeng H; Whitlock JA; Adamson PC; Hunger SP; Carroll WL
Pediatr Blood Cancer; 2015 Jul; 62(7):1171-5. PubMed ID: 25732247
[TBL] [Abstract][Full Text] [Related]
3. Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives.
Franca R; Favretto D; Granzotto M; Decorti G; Rabusin M; Stocco G
Curr Med Chem; 2017; 24(11):1050-1065. PubMed ID: 28088906
[TBL] [Abstract][Full Text] [Related]
4. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
Farhadfar N; Litzow MR
Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
[TBL] [Abstract][Full Text] [Related]
5. Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Corbacioglu S; Eber S; Gungor T; Hummerjohann J; Niggli F
J Pediatr Hematol Oncol; 2003 Apr; 25(4):327-9. PubMed ID: 12679650
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
Raetz EA; Cairo MS; Borowitz MJ; Blaney SM; Krailo MD; Leil TA; Reid JM; Goldenberg DM; Wegener WA; Carroll WL; Adamson PC;
J Clin Oncol; 2008 Aug; 26(22):3756-62. PubMed ID: 18669463
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract][Full Text] [Related]
8. Novel antibody therapy in acute lymphoblastic leukemia.
Kochuparambil ST; Litzow MR
Curr Hematol Malig Rep; 2014 Jun; 9(2):165-73. PubMed ID: 24623281
[TBL] [Abstract][Full Text] [Related]
9. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
Chevallier P; Eugene T; Robillard N; Isnard F; Nicolini F; Escoffre-Barbe M; Huguet F; Hunault M; Marcais A; Gaschet J; Cherel M; Guillaume T; Delaunay J; Peterlin P; Eveillard M; Thomas X; Ifrah N; Lapusan S; Bodet-Milin C; Barbet J; Faivre-Chauvet A; Ferrer L; Bene MC; Le Houerou C; Goldenberg DM; Wegener WA; Kraeber-Bodéré F
Lancet Haematol; 2015 Mar; 2(3):e108-17. PubMed ID: 26687796
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
11. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
George B; Kantarjian H; Jabbour E; Jain N
Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
13. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.
Rytting M; Triche L; Thomas D; O'Brien S; Kantarjian H
Pediatr Blood Cancer; 2014 Feb; 61(2):369-72. PubMed ID: 24000241
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
15. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
16. Early relapse after rituximab chemoimmunotherapy.
Kiss F; Buslig J; Szegedi I; Scholtz B; Kappelmayer J; Kiss C
Pediatr Blood Cancer; 2008 Feb; 50(2):372-5. PubMed ID: 17973316
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
Hoelzer D
Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies in adult acute lymphoblastic leukemia.
Kantarjian H
Hematology; 2012 Apr; 17 Suppl 1():S52-4. PubMed ID: 22507779
[TBL] [Abstract][Full Text] [Related]
19. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Yurkiewicz IR; Muffly L; Liedtke M
Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
[TBL] [Abstract][Full Text] [Related]
20. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]